daunorubicin has been researched along with vidarabine in 40 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (10.00) | 18.2507 |
2000's | 14 (35.00) | 29.6817 |
2010's | 18 (45.00) | 24.3611 |
2020's | 4 (10.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
Calvert, L; Deisseroth, AB; Feldman, E; Hester, J; Kantarjian, HM; Korbling, M; Liang, J; Rios, MB; Smith, TL; Talpaz, M | 1 |
Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
Higashi, Y; Pallis, M; Russell, NH; Turzanski, J | 1 |
Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
Bown, N; Hamilton, PJ; Jackson, GH; Reid, MM; Taylor, PR; Wells, AW | 1 |
Appelbaum, FR | 1 |
Alexander, HD; Humphreys, MW; Kettle, PJ; McGrattan, P | 1 |
Albitar, M; Alvarado, Y; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Thomas, DA; Tsimberidou, AM; Verstovsek, S; Wierda, W | 1 |
Davis, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Shen, Y; Thomas, MB; Yang, Y | 1 |
Baker, RJ; Foroni, L; Ganeshaguru, K; Jones, DT; Mehta, AB; Mitchell, WA; Prentice, HG; Wickremasinghe, RG | 1 |
Cotter, M; Enright, H | 1 |
Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C | 1 |
Abdall, N; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gatto, S; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R; Venturino, C | 1 |
Grosicki, S; Hołowiecki, J; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Seferynska, I; Skotnicki, AB; Warzocha, K; Zdziarska, B | 1 |
Bengtzen, S; Concha, H; Lehmann, S; Merup, M; Möllgård, L; Nahi, H; Paul, C; Selivanova, G; Svensson, A; Wiman, KG | 1 |
Camera, A; Cantore, N; Ferrara, F; Grimaldi, F; Guerriero, A; Luciano, L; Mastrullo, L; Mele, G; Mettivier, V; Miraglia, E; Palmieri, S; Rinaldi, CR; Rotoli, B | 1 |
Briel, J; Gocke, CD; Hess, AD; Kanakry, CG; Karp, JE; Kos, F; Levitsky, H; Luznik, L; Meyer, C; Smith, BD; Thoburn, C | 1 |
Ali, D; Bengtzén, S; Deneberg, S; Jönsson-Videsäter, K; Lehmann, S; Nahi, H; Paul, C | 1 |
Solis, EC | 1 |
Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
Aleinikova, O; Armendariz, H; Bertrand, Y; Creutzig, U; Dworzak, M; Gibson, BE; Ha, SY; Hasle, H; Hovi, L; Kaspers, GJ; Leverger, GG; Maschan, A; Razzouk, BI; Reinhardt, D; Rizzari, C; Smisek, P; Smith, O; Stark, B; Tamminga, RY; Zimmermann, M | 1 |
Cao, X; Cen, J; Chen, Z; Gu, W; Li, M; Liu, Y; Xiang, L; Xie, X; Zhen, X | 1 |
Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U | 1 |
Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
Bacigalupo, A; Ballerini, F; Clavio, M; Cruciani, F; De Astis, E; Di Grazia, C; Galaverna, F; Ghiggi, C; Ghiso, A; Gobbi, M; Guolo, F; Lemoli, RM; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G; Raiola, AM; Varaldo, R | 1 |
Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY | 1 |
Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
Ali, A; Burnett, AK; Cahalin, P; Freeman, S; Hills, RK; Hunter, A; Nielsen, OJ; Russell, NH; Thomas, IF | 1 |
Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I | 1 |
Anderson, E; Bone, H; Heywood, J; Mayer, L; Mehta, P; Rees, B; Reynolds, D; Robinson, G; Salisbury, V | 1 |
Huang, Y; Liu, DD; Lv, TT; Xu, J; Yuan, GL; Zhou, XF | 1 |
Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR | 1 |
DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF | 1 |
5 review(s) available for daunorubicin and vidarabine
Article | Year |
---|---|
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
Tetrasomy 13 as the sole cytogenetic abnormality in acute myeloid leukemia M1 without maturation.
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 13; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine; Vidarabine | 2002 |
A novel t(15;17) translocation in acute myeloid leukaemia not associated with PML/RARalpha rearrangement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Breakage; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; DNA-Binding Proteins; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Acute; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins; Remission Induction; Salvage Therapy; Thioguanine; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Vidarabine | 2003 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
9 trial(s) available for daunorubicin and vidarabine
Article | Year |
---|---|
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine | 2004 |
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Liposomes; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Poland; Remission Induction; Vidarabine | 2008 |
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Time Factors; Vidarabine | 2009 |
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult | 2012 |
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Odds Ratio; Remission Induction; Research Design; Treatment Outcome; Vidarabine | 2013 |
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine | 2022 |
26 other study(ies) available for daunorubicin and vidarabine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Separation; Cytarabine; Daunorubicin; Diploidy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 1995 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic l
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Clone Cells; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vidarabine | 2000 |
Erythroleukaemia in the north of England: a population based study.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Cytogenetics; Daunorubicin; England; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Prospective Studies; Risk; Survival Rate; Thioguanine; Treatment Outcome; Vidarabine | 2001 |
Hematopoietic cell transplantation beyond first remission.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Nuclear Family; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubicin; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Vidarabine; Vincristine | 2003 |
Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2003 |
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase 3; Caspases; Cytarabine; Daunorubicin; Drug Interactions; Humans; Leukemia, Myeloid; Membrane Glycoproteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine | 2003 |
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Furans; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Nerve Tissue Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cytarabine; Cytosine; Daunorubicin; Etoposide; Female; Flavonoids; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Vidarabine; Young Adult | 2011 |
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Aza Compounds; Base Sequence; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Genes, p53; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mutation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF; Vidarabine | 2011 |
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; Nucleophosmin; Peripheral Blood Stem Cell Transplantation; Prognosis; Real-Time Polymerase Chain Reaction; RNA, Neoplasm; Survival Analysis; Trans-Activators; Transplantation, Autologous; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine; Young Adult | 2013 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2014 |
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; United Kingdom; Vidarabine; Young Adult | 2018 |
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine | 2019 |
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
Topics: Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; THP-1 Cells; Vidarabine | 2018 |
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Topics: Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Calreticulin; Cell Line, Tumor; Cytarabine; Daunorubicin; Dendritic Cells; Etoposide; Extracellular Space; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Immunogenic Cell Death; Leukemia, Myeloid, Acute; Lymphocyte Activation; Neoplasm Proteins; Organelles; Protein Transport; T-Lymphocyte Subsets; Vidarabine | 2020 |